{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T05:13:54Z","timestamp":1778303634999,"version":"3.51.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,8]]},"DOI":"10.7759\/cureus.108523","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T05:04:50Z","timestamp":1778303090000},"source":"Crossref","is-referenced-by-count":0,"title":["Drug Retention of First-Line Biologic Therapies in Rheumatoid Arthritis: Real-World Evidence From a Moroccan Cohort"],"prefix":"10.7759","author":[{"given":"El Marbouh","family":"El Kacem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abderrahim","family":"Majjad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wissal","family":"Belhadj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamza","family":"Toufik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laila","family":"Taoubane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Bezza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen JS","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016, 388:2023-38. 10.1016\/S0140-6736(16)30173-8","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen JS","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RB, Bergstra SA, et al.. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023, 82:3-18. 10.1136\/ard-2022-223356","journal-title":"Ann Rheum Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24596","article-title":"2021 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel L","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, et al.. 2021 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021, 73:924-39. 10.1002\/acr.24596","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X251325665","article-title":"Primary non-response in inflammatory arthritis treated with biologics and targeted therapies in daily clinical practice","volume":"17","author":"Leon L","year":"2025","unstructured":"Leon L, Freites-Nu\u00f1ez D, Toledano E, et al.. Primary non-response in inflammatory arthritis treated with biologics and targeted therapies in daily clinical practice. Ther Adv Musculoskelet Dis. 2025, 17:1759720X251325665. 10.1177\/1759720X251325665","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1349533","article-title":"Retention rate of biologic and targeted synthetic anti-rheumatic drugs in elderly rheumatoid arthritis patients: data from GISEA registry","volume":"11","author":"Manfredi A","year":"2024","unstructured":"Manfredi A, Fornaro M, Bazzani C, et al.. Retention rate of biologic and targeted synthetic anti-rheumatic drugs in elderly rheumatoid arthritis patients: data from GISEA registry. Front Med (Lausanne). 2024, 11:1349533. 10.3389\/fmed.2024.1349533","journal-title":"Front Med (Lausanne)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha D","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, et al.. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010, 69:1580-8. 10.1136\/ard.2010.138461","journal-title":"Ann Rheum Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2009.10.001","article-title":"The Disease Activity Score and the EULAR response criteria","volume":"35","author":"Fransen J","year":"2009","unstructured":"Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Rheum Dis Clin North Am. 2009, 35:745-57, vii-viii. 10.1016\/j.rdc.2009.10.001","journal-title":"Rheum Dis Clin North Am"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/ar1740","article-title":"Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score","volume":"7","author":"Aletaha D","year":"2005","unstructured":"Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, Smolen JS. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther. 2005, 7:R796-806. 10.1186\/ar1740","journal-title":"Arthritis Res Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg072","article-title":"A simplified disease activity index for rheumatoid arthritis for use in clinical practice","volume":"42","author":"Smolen JS","year":"2003","unstructured":"Smolen JS, Breedveld FC, Schiff MH, et al.. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford). 2003, 42:244-57. 10.1093\/rheumatology\/keg072","journal-title":"Rheumatology (Oxford)"},{"key":"ref10","article-title":"Measurement of the functional capacity in rheumatoid polyarthritis: a French adaptation of the Health Assessment Questionnaire (HAQ) (Article in French)","volume":"58","author":"Guillemin F","year":"1991","unstructured":"Guillemin F, Brain\u00e7on S, Pourel J. Measurement of the functional capacity in rheumatoid polyarthritis: a French adaptation of the Health Assessment Questionnaire (HAQ) (Article in French). Rev Rhum Mal Osteoartic. 1991, 58:459-65.","journal-title":"Rev Rhum Mal Osteoartic"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(74)90884-8","article-title":"Measurement of pain","volume":"2","author":"Huskisson EC","year":"1974","unstructured":"Huskisson EC. Measurement of pain. Lancet. 1974, 2:1127-31. 10.1016\/s0140-6736(74)90884-8","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-48537-z","article-title":"Real-world retention rates of biologics in patients with rheumatoid arthritis","volume":"13","author":"Takami K","year":"2023","unstructured":"Takami K, Tsuji S. Real-world retention rates of biologics in patients with rheumatoid arthritis. Sci Rep. 2023, 13:21170. 10.1038\/s41598-023-48537-z","journal-title":"Sci Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-02380-z","article-title":"Long-term remission and biologic persistence rates: 12-year real-world data","volume":"23","author":"Murray K","year":"2021","unstructured":"Murray K, Turk M, Alammari Y, et al.. Long-term remission and biologic persistence rates: 12-year real-world data. Arthritis Res Ther. 2021, 23:25. 10.1186\/s13075-020-02380-z","journal-title":"Arthritis Res Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11646","article-title":"Real-world treatment and care patterns in patients with rheumatoid arthritis initiating first-line tumor necrosis factor inhibitor therapy in the United States","volume":"6","author":"Edgerton C","year":"2024","unstructured":"Edgerton C, Frick A, Helfgott S, et al.. Real-world treatment and care patterns in patients with rheumatoid arthritis initiating first-line tumor necrosis factor inhibitor therapy in the United States. ACR Open Rheumatol. 2024, 6:179-88. 10.1002\/acr2.11646","journal-title":"ACR Open Rheumatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/art.27227","article-title":"Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry","volume":"62","author":"Hetland ML","year":"2010","unstructured":"Hetland ML, Christensen IJ, Tarp U, et al.. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010, 62:22-32. 10.1002\/art.27227","journal-title":"Arthritis Rheum"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/491053-drug-retention-of-first-line-biologic-therapies-in-rheumatoid-arthritis-real-world-evidence-from-a-moroccan-cohort","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T05:04:51Z","timestamp":1778303091000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/491053-drug-retention-of-first-line-biologic-therapies-in-rheumatoid-arthritis-real-world-evidence-from-a-moroccan-cohort"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.108523","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,8]]}}}